Phase 1 study of MDM2 antagonist ASTX295 in patients with solid tumors with wild-type TP53

被引：1
|
作者：
Dumbrava, Ecaterina E.
Iwamoto, Fabio M.
Agulnik, Mark
Milhem, Mohammed
Tolcher, Anthony W.
Chugh, Rashmi
Demeure, Michael J.
Mita, Alain
Demel, Kurt
Diamond, Mark
Mirakhur, Beloo
Wilson, Laksmi
Oganesian, Aram
Chan, Danna
Keer, Harold N.
Taylor, Jason
Sims, Martin J.
Biondo, Andrea
Jueliger, Simone
Spira, Alexander
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT066
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT066
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A phase I study of the MDM2 inhibitor AMG 232 in patients with advanced p53 wild type (p53WT) solid tumors or multiple myeloma
    Langenberg, M. H.
    Gluck, L.
    Weger, V.
    Frank, R.
    Eskens, F.
    Blay, J. Y.
    Soria, J. C.
    Chawla, S.
    Gounder, M.
    Wagner, A.
    Zhang, Y.
    Kambuj, P.
    Loberg, R.
    Henary, H.
    [J]. EUROPEAN JOURNAL OF CANCER, 2016, 69 : S34 - S34
  • [42] TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients
    Di Vuolo, Valeria
    Buonaguro, Luigi
    Izzo, Francesco
    Losito, Simona
    Botti, Gerardo
    Buonaguro, Franco M.
    Tornesello, Maria Lina
    [J]. INFECTIOUS AGENTS AND CANCER, 2011, 6
  • [43] Association of TP53 and MDM2 polymorphisms with survival in bladder cancer patients treated with chemoradiotherapy
    Shinohara, Asano
    Sakano, Shigeru
    Hinoda, Yuji
    Nishijima, Jun
    Kawai, Yoshihisa
    Misumi, Taku
    Nagao, Kazuhiro
    Hara, Takahiko
    Matsuyama, Hideyasu
    [J]. CANCER SCIENCE, 2009, 100 (12): : 2376 - 2382
  • [44] Phase 1/1b Study of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, As Monotherapy or in Combination with Cytarabine for the Treatment of Relapsed/Refractory AML and Advanced MDS with TP53 Wild-Type
    Sallman, David A.
    Borate, Uma
    Cull, Elizabeth H.
    Donnellan, William B.
    Komrokji, Rami S.
    Steidl, Ulrich G.
    Corvez, Maria M.
    Payton, Marie
    Annis, D. Allen
    Pinchasik, Dawn
    Aivado, Manuel
    Verma, Amit
    [J]. BLOOD, 2018, 132
  • [45] Status Analysis of the Genes MYCN, MDM2 and TP53 and Protein Expression of MDM2, P53 and PRB in Patients with Retinoblastoma Underwent Enucleation
    Carvalho Filho, N.
    Cunha, I. Werneck
    Ribeiro, K. Braga
    Antoneli, C. B. Gianotti
    [J]. PEDIATRIC BLOOD & CANCER, 2016, 63 : S144 - S144
  • [46] Complete loss of wild-type TP53 in a nontransformed human epithelial cell line is preceded by a phase during which a heterozygous TP53 mutant effectively outgrows the homozygous wild-type cells
    Villadsen, R
    Nielsen, KV
    Bolund, L
    Briand, P
    [J]. CANCER GENETICS AND CYTOGENETICS, 2000, 116 (01) : 28 - 34
  • [47] The MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2
    Gu, Lubing
    Zhu, Ningxi
    Findley, Harry W.
    Zhou, Muxiang
    [J]. BLOOD, 2007, 110 (11) : 137B - 137B
  • [48] MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2
    Gu, L.
    Zhu, N.
    Findley, H. W.
    Zhou, M.
    [J]. LEUKEMIA, 2008, 22 (04) : 730 - 739
  • [49] MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2
    L Gu
    N Zhu
    H W Findley
    M Zhou
    [J]. Leukemia, 2008, 22 : 730 - 739
  • [50] MDM2 antagonist Nutlin-3a protects wild-type p53 cancer cells from paclitaxel
    SHEN HongChang
    [J]. Science Bulletin, 2012, (09) : 1007 - 1012
12345